Johnson & Johnson to Pay $181M Settlement Over Risperdal Marketing

Johnson & Johnson has agreed to a $181 million settlement with 37 states and the District of Columbia, resolving claims that it improperly marketed its antipsychotic drug Risperdal, according to a news release.

The complaint charged that J&J subsidiary Janssen Pharmaceuticals promoted Risperdal for unapproved uses, including dementia in elderly patients, schizophrenia and bi-polar disorder in children and adolescents, and depression to name a few. These uses were allegedly not approved by the Food and Drug Administration.

States receiving a portion of the settlement are Alabama, Arizona, Colorado, Connecticut, Delaware, District of Columbia, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.

More Articles on Pharmaceutical Companies and Fraud:

Johnson & Johnson Slapped With $1.1B Fine for Risperdal Marketing
Drugmakers Pay More Than $8B in Fraud Fines in Past Decade
Insurers Tailor Plans for Healthcare Executives Facing Misdemeanor Fraud Charges

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars